Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS, a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center in Montvale, New Jersey.

Articles

Looking Ahead: Potential Sequencing Strategies and Focusing On a Patient-Centered Approach to Treatment of HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how sequencing strategies for multiple HER2-targeted therapies will require careful consideration of patient characteristics, disease burden, and prior treatments, with oral tyrosine kinase inhibitors potentially preferred first due to better tolerability and CNS activity, while combination approaches remain investigational pending safety and efficacy data.

Emerging Oral HER2-Targeted TKIs (Zongertinib and Sevabertinib): Efficacy and Safety in HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how emerging oral tyrosine kinase inhibitors like zongertinib (HER2-selective) and sevabertinib (HER2/EGFR dual inhibitor) offer promising alternatives to antibody-drug conjugates with improved tolerability profiles, better central nervous system penetration, and robust response rates in the 60% to 70% range for second-line treatment.

Recognizing and Treating Interstitial Lung Disease Associated With Trastuzumab Deruxtecan

June 13th 2025

Panelists discuss how interstitial lung disease represents a critical and potentially cryptic toxicity occurring in 10% to 15% of patients receiving HER2 antibody-drug conjugates, requiring vigilant monitoring, prompt recognition of subtle symptoms like dry cough, and aggressive management with steroids and pulmonary consultation.

Antibody-Drug Conjugate Efficacy and Safety in HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how antibody drug conjugates like trastuzumab deruxtecan work as “Trojan horses” to deliver chemotherapy directly to tumor cells, providing effective second-line treatment for patients with HER2-mutated disease but requiring careful management of chemotherapy-like adverse effects, including significant toxicities.

Clinical Implications and Frontline Treatment of HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how patients with HER2-mutated lung cancer represent a high-risk population with aggressive biology and propensity for brain metastases, currently treated with standard chemotherapy in the frontline setting while awaiting clinical trials that may move HER2-targeted agents to first-line treatment.

HER2 Alteration Testing In Advanced and Metastatic NSCLC

June 13th 2025

Panelists discuss how comprehensive next-generation sequencing testing is essential for identifying HER2 mutations in patients with stage IV non–small cell lung cancer, distinguishing between HER2 mutations (detected by DNA sequencing) and HER2 overexpression/amplification (detected by immunohistochemistry).

Dr Preeshagul on Emerging Treatments in SCLC

June 3rd 2025

Isabel Preeshagul, DO, MBS, highlights the role of emerging therapies in the SCLC landscape, including tarlatamab and durvalumab.

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

October 7th 2024

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

It’s Not a Small World for Small Cell Lung Cancer Treatment

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.

Living In a Targeted Therapy Revolution of NSCLC

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, highlight results with immunotherapy in the neoadjuvant and stage IV setting in lung cancer that were presented at the 2021 World Conference on Lung Cancer and the 2021 ESMO Congress.

Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss breakthroughs in adjuvant immunotherapy in lung cancer from data presented at the 2021 ESMO Congress and 2021 World Conference on Lung Cancer.

Dr. Preeshagul on Education for Biosimilars in Oncology

October 22nd 2019

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.